CN1615915A - Medicine for treating diabetes - Google Patents
Medicine for treating diabetes Download PDFInfo
- Publication number
- CN1615915A CN1615915A CN 200310107683 CN200310107683A CN1615915A CN 1615915 A CN1615915 A CN 1615915A CN 200310107683 CN200310107683 CN 200310107683 CN 200310107683 A CN200310107683 A CN 200310107683A CN 1615915 A CN1615915 A CN 1615915A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- treatment
- diabetes
- matched group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title claims description 10
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 239000009636 Huang Qi Substances 0.000 claims description 16
- 241000756943 Codonopsis Species 0.000 claims description 10
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 10
- 239000008517 radix Trichosanthis Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 29
- 230000035922 thirst Effects 0.000 abstract description 10
- 230000007812 deficiency Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 231100001231 less toxic Toxicity 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 206010013954 Dysphoria Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 235000019615 sensations Nutrition 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000035900 sweating Effects 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 208000007976 Ketosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940084094 glyburide 2.5 mg Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000009592 kidney function test Methods 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine for assisting treatment of diabetes with deficiency of both vital energy and Yin is prepared with ten kinds of Chinese medicinal materials, including trichosanthes root, ophiopogon root, tuckahoe, astragalus root, licorice, etc. It has excellent functions of benefiting vital energy, nourishing Yin and promoting the secretion of saliva to relieve thirst. The present invention has the advantages of reasonable recipe, simple technological process, determined curative effect, less toxic side effect and no medicine dependence.
Description
Technical field: the present invention relates to a kind of medicine that is used for the syndrome of deficiency of both qi and yin treatment of diabetes, being specifically related to a kind of is the medicine that raw material mixes with the Chinese herbal medicine.
Background technology: diabetes threaten the healthy of people, and how curing diabetes is a great problems of present medical circle.Use western medicine, the toxic and side effects of medicine of long duration will highlight, and therapeutic effect also varies with each individual, and is not very good; Supplementation with insulin can produce dependency again, in case drug withdrawal, disease rebounds more very; With the diet control glucose in urine is a good way, but patient's diet desire is wayward, can not tackle the problem at its root; With Chinese herbal treatment diabetes a kind of relatively way of reality of can yet be regarded as, and long history is also arranged with the Chinese herbal treatment diabetes, little with its toxic and side effects, can not produce dependency, also accepted and promise well by the patient easily, but up to the present, also do not have in the Chinese medicine the inside of treatment diabetes a kind of cry the Chinese medicine brand of ringing, though the Chinese medicine of these treatment diabetes is each has something to recommend him, total effective percentage, the scope of indication etc. all remain further to improve and enlarge.
Summary of the invention: the purpose of this invention is to provide a kind of medicine that is used for the treatment of diabetes, it has reasonable recipe, determined curative effect, the indication scope is wide, toxic and side effects is little characteristics.The present invention is mixed by weight by following raw materials according: Radix Trichosanthis 80g～130g, Radix Ophiopogonis 50g～100g, Poria 50g～100g, Radix Astragali 50g～100g, Radix Glycyrrhizae 50g～100g, Radix Rehmanniae 50g～100g, Radix Puerariae 80g～130g, Radix Codonopsis 120g～180g, Fructus Mume 50g～100g, Fructus Schisandrae Chinensis 50g～100g; Preferred version of the present invention is to be mixed by weight by following raw materials according: Radix Trichosanthis 95g～120g, Radix Ophiopogonis 65g～90g, Poria 65g～90g, Radix Astragali 65g～90g, Radix Glycyrrhizae 65g～90g, Radix Rehmanniae 65g～90g, Radix Puerariae 95g～120g, Radix Codonopsis 135g～165g, Fructus Mume 65g～90g, Fructus Schisandrae Chinensis 65g～90g; Preferred plan of the present invention is to be mixed by weight by following raw materials according: Radix Trichosanthis 112.5g, Radix Ophiopogonis 75g, Poria 75g, Radix Astragali 75g, Radix Glycyrrhizae 75g, Radix Rehmanniae 75g, Radix Puerariae 112.5g, Radix Codonopsis 150g, Fructus Mume 75g, Fructus Schisandrae Chinensis 75g.Manufacture method of the present invention is: get Radix Trichosanthis 112.5g, Radix Ophiopogonis 75g, Poria 75g, Radix Astragali 75g, Radix Glycyrrhizae 75g, Radix Rehmanniae 75g, Radix Puerariae 112.5g, Radix Codonopsis 150g, Fructus Mume 75g, Fructus Schisandrae Chinensis 75g, above ten flavor medicated powder are broken into coarse powder, decoct with water twice, add the water of 12 times of amounts of ten flavor medicines for the first time, decocted two hours, add for the second time the water of 8 times of amounts of ten flavor medicines, decocted 1 hour, merge decoction liquor, filter, filtrate is concentrated into relative density 1.20 ± 0.2 (50 ℃), puts coldly, adds water to 1000ml, filter, add sodium benzoate 2g, stir, make its dissolving, filter, embedding, sterilization promptly gets (the safe mixture that gets of sugar).The raw material Radix Astragali of the present invention is one or both the mixing wherein of Radix Astragali or the sweet Radix Astragali.
Radix Puerariae among the present invention can be used for the thirsty or diabete of calentura, and analgesic effect of promoting the production of body fluid is arranged; Radix Trichosanthis is longer than clearing away heat and promoting production of body fluid, is used for the thirsty and card such as quench one's thirst of calentura Tianjin wound; Radix Rehmanniae has the YIN nourishing and the production of body fluid promoting effect, is used for consumption of body fluid caused by febrile disease, red tongue xerostomia, or card such as thirsty polydipsia; Poria has good hypoglycemic activity; The Radix Astragali, Radix Codonopsis, Fructus Schisandrae Chinensis, Radix Glycyrrhizae, Radix Ophiopogonis are all tonic, have strengthening vital QI to eliminate pathogenic factors, improve symptom, promote the restorative early function of body; Fructus Mume has the effect in quenching the thirst, transferring, more than ten the flavor Chinese medicines compatibilities have the effect of good supplementing QI and nourishing YIN, promoting the production of body fluid to quench thirst.Can be used for the syndrome of deficiency of both qi and yin treatment of diabetes, can improve fatigue and weakness, the symptoms such as lazy speech, thirst and liking drink, dysphoria with feverish sensation in the chest palms and soles, spontaneous sweating of breathing hard.
Medicine of the present invention is used for recovery of melituria 107 routine clinical trials and sums up:
One, physical data:
(1) case source:
According to the clinical trial requirement, select to be in hospital and the outpatient counts 144 examples, inpatient's 96 examples wherein, outpatient's 48 examples, number of hospitalized accounts for total case load 66.7%.
(2) sex:
Among the 144 routine patients, male's 80 examples, women's 64 examples, man: woman=1.25: 1.Two groups of sex compositioies are than as shown in table 1.
Table 1
Group example number men and women
Treatment organizes 107 59 48
Matched group 37 20 17
X
2＝0.028 P＞0.05
Two groups of sex ratios, no significant difference between place P＞0.05, two group by statistics.
(3) age:
Two groups of patient age areal area and mean age are as shown in table 2.
Table 2
The age distribution mean age
Group example number
＜40 41… 51… ＞60 X+SD
Treatment organizes 107 9 31 54 13 58.74 ± 8.69
Matched group 37 3 11 18 5 57.97 ± 9.12
Learn by statistics and handle, two groups of patient ages distribute and the mean age comparison no significant difference (P＞0.05).
(4) two groups of patient's courses of disease are more as shown in table 3:
Table 3
Course of disease distribution (moon) (in 24 months)
Group example number
0.5--6.1-------------12.1---------------18.1------------------24
Treatment organizes 107 16 42 32 17
Matched group 37 5 16 10 6
X
2＝0.189 P＞0.05
Two groups of courses of disease are relatively learned by statistics and are handled no significant difference (P＞0.05).
(5) two groups of tcm symptoms and divide stage more as shown in table 4:
Table 4
Treatment group matched group
GP TH group (107) grouping matched group (37)
Tcm symptom
The normal slight moderate severe of normal slight moderate severe
Fatigue and weakness 38 53 16 14 18 5
Spontaneous sweating 27 26 38 16 99 13 6
The lazyness of breathing hard speech 11 26 40 30 89 12 8
Thirst and liking drink 15 20 37 35 48 13 12
Dysphoria with feverish sensation in the chest palms and soles 15 34 33 25 4 12 10 11
Palpitation and insomnia 21 42 27 17 8 15 95
The red constipation 10 37 40 20 3 13 14 7 of urinating
Red tongue with a little fluid 76 31 27 10
Thready and rapid pulse without strength 60 47 20 17
Main Syndrome in TCM disease and branch stage compare no significant difference (P＞0.05) before two groups of treatments.
Find out that from above physical data analysis two groups are divided between stage at sex, age, the course of disease and traditional Chinese medical science main symptom, difference is not significantly (P＞0.05) all, so two groups of patients have comparability.
Two, case choice criteria:
(1) diagnostic criteria:
1, tcm diagnosis standard:
All have thirsty polydipsia, the easy flesh of rapid digestion of food, frequent micturition and sweet, body is gradually seen symptom person such as become thin and can be made a definite diagnosis.
2, Chinese medical discrimination:
Deficiency of both QI and YIN disease.
Fatigue and weakness, spontaneous sweating, the lazy speech of breathing hard, thirst and liking drink, dysphoria with feverish sensation in the chest palms and soles, palpitation and insomnia, the red constipation of urinating, red tongue with a little fluid, corpulent tongue are big, thin fur or flower stripping, thready pulse or count accurately.
3, Western medicine diagnose standard:
(1) diabetic symptom is arranged, blood glucose 〉=11.1mmol/L (200mg/dl), or fasting glucose 〉=7.8mmol/L (140mg/dl) any time.
(2) diabetic symptom is arranged and blood glucose does not reach above-mentioned standard, carry out 75g oral glucose tolerance test (OGTT), 2 hours blood glucose 〉=11.1mmol/L (200mg/dl).
(3), remove above-mentioned standard exterior palpi and add a standard in addition, promptly OGTT1 hour blood glucose 〉=11.1mmol/L (200mg/dl), or another time fasting glucose 〉=7.8mmol/L (140mg/dl) as the non-diabetic symptom.
(2) test case standard:
1, include the case standard in:
Allly meet the Western medicine diagnose standard and Chinese medical discrimination belongs to deficiency of both QI and YIN pattern of syndrome person, can include the observation case in.
2, get rid of case standard (comprising inadaptation or rejecting standard):
(1) though patient's blood glucose before with new drug is higher than normally,, increase fasting glucose＜7.8mmol/L (140mg/dl) such as activity by diet control, or 2 hours after the meal blood glucose＜11.1mmol/L (200mg/dl).
(2) age is at under-18s, or the over-65s patient, and pregnant women breast-feeding their children are to this medicine allergy sufferers.
(3) noncooperationist's (refer to cooperate diet control or not medication and the person of affecting the treatment in accordance with regulations).
(4) complication such as severe cardiac, liver, kidney are arranged, or be associated with other serious primary disease, the psychotic.
(5) in nearly one month diabetes ketosis, ketoacidosis and the infected are arranged.
(6) therapy discontinued less than the regulation observation period can't be judged the infull person of curative effect or data.
Three, observation index:
1, safety observation:
(1) general physical examination.
(2) blood, urine, just routine test.
(3) heart, liver, kidney function test.
2, health giving quality observation
(1) detailed medical history-taking, understanding patient's diet situation, activity, mental status, Diabetes Mellitus Knowledge, stress state etc. influence the factor of change of blood sugar, observe the situation of change of main clinic symptoms and body weight.
(2) reach 2 hours after the meal blood sugar test on an empty stomach, weekly after the medication.
(3) twenty-four-hour urine sugar detection by quantitative, weekly after the medication.
(4) detection of glycolated hemoglobin.
(5) plasma insulin, C peptide detect.
(6) glucagon detects.
(7) insulin tolerance test.
(8) insular cellular antibody, Insulin receptor INSR, antibody test.
More than (1) (2) (3) must do, other can be done according to the choosing of the needs of disease.
Treat preceding 4 weeks, checked fasting glucose, glucose in urine (quantitative or qualitative) every 10～14 days, continuous 3 times, 3 averages are as the preceding control value of treatment.
From observing from this very day, require the patient to adhere to diet control for a long time.Roughly the staple food regulation is as follows by different labor intensity and build: have a rest or overproof body weight person's staple food every day is controlled at 250～300g; The labor in general person, every day 300～350g; Heavy worker 400～500g every day.Take the circumstances into consideration beyond the staple food to replenish by non-staple foodstuff.
Four, curative effect determinate standard:
(1) total effects is judged:
1, produce effects: treatment back symptom disappears fasting glucose＜7.2mmol/L (130mg/dl) substantially.2 hours after the meal blood glucose＜8.3mmol/L (150mg/dl), twenty-four-hour urine sugar amount＜10.0g; Or blood glucose, twenty-four-hour urine sugar quantitatively descends more than 30% before the treatment.
2, effective:
Treatment back symptom is obviously improved, fasting glucose＜8.3mmol/L (150mg/dl), 2 hours after the meal blood glucose＜10.0mmol/L (180mg/dl), twenty-four-hour urine sugar quantitatively＜25g; Or blood glucose, twenty-four-hour urine sugar quantitatively descends more than 10% before the treatment.
3, invalid:
Treatment back symptom does not have obvious improvement, blood glucose, glucose in urine and descends and do not reach These parameters.
(2) symptom efficacy determination:
Divide stage improvement situation to judge by symptom, symptom by severe, moderate, the slight Chang Zhewei transference cure of becoming a full member; Transferring slight person to by severe is produce effects; Severe transfers moderate to or transfers slight person to for effective by moderate.
Five, test method:
Take random packet principle (contrast in 3: 1), single blind controlled trial.
(1) treatment group: give glyburide 2.5mg oral three times on the one half an hour ante cibum, take the each 10ml of medicine of the present invention simultaneously, 4 times on the one, oral.
(2) matched group: give glyburide 2.5mg oral three times on the one half an hour ante cibum.
(3) per 4 weeks are a course of treatment.
Six, observed result:
(1) medicine of the present invention is effective to cardinal symptom, relatively sees Table 5 with matched group.
(2) medicine total effects of the present invention relatively sees Table 6 with the matched group curative effect.
Table 6
Curative effect
Group example number
Produce effects (%) is (%) invalid (%) effectively
Treatment organizes 107 22 (20.56) 57 (53.3) 28 (26.14)
Matched group 37 6 (16.2) 18 (48.65) 13 (35.1)
As seen from Table 6, treatment group effective percentage 73.86%, matched group effective percentage 64.85%.Treatment group effective percentage is better than matched group.There were significant differences (P＜0.05) learn to handle the latter two by statistics.
Table 5 medicine of the present invention compares cardinal symptom curative effect and matched group
The tcm symptom disappearance produce effects invalid P that takes a turn for the better
Treatment organizes 48 27 98
(92) (52.2) (29.3) (9.8) (8.7)
Thirst and liking drink
＜0.05
Matched group 9888
(33) (27.2) (24.2) (24.2) (24.2)
Treatment organizes 66 21 10 10
(107) (61.6) (19.6) (9.34) (9.34)
Fatigue and weakness
＜0.05
Matched group 16 687
(37) (43.2) (16.2) (21.6) (18.9)
Treatment organizes 47 20 17 12
(96) (48.9) (20.8) (17.7) (12.5)
The lazyness of breathing hard speech
＜0.05
Matched group 6698
(29) (20.69) (20.69) (31.0) (27.58)
Treatment organizes 41 18 22 11
(92) (44.5) (19.5) (23.9) (11.9)
Dysphoria with feverish sensation in the chest palms and soles
＜0.05
Matched group 877 11
(33) (24.2) (21.2) (21.2) (33.3)
Treatment organizes 15 9 14 59
(97) (15.5) (9.3) (14.4) (60.8)
The red constipation of urinating
＜0.05
Matched group 228 22
(34) (5.88) (5.88) (23.53) (64.70)
Treatment organizes 18 20 17 31
(86) (20.9) (23.2) (19.7) (36.0)
Palpitation and insomnia
＜0.05
Matched group 069 14
(29) (20.6) (31.0) (18.2)
Treatment organizes 33 23 14 10
(80) (41.3) (28.7) (17.5) (12.5)
Spontaneous sweating
＜0.05
Matched group 5689
(28) (17.85) (21.42) (28.57) (32.14)
Medicine of the present invention as seen from Table 5 is to thirst and liking drink, fatigue and weakness, the lazy speech of breathing hard, dysphoria with feverish sensation in the chest palms and soles, the diseases such as red constipation, palpitation and insomnia, spontaneous sweating of urinating, effect is all better, and the above rate of its produce effects is respectively 81.5%, 81.2%, 69.7%, 64%, 24.8%, 44.1%, 70%.Compare with matched group, the two has notable difference (P＜0.05).
Six, safety measurement result
The treatment group is done blood, urine, just routine and the heart, liver, kidney function test to 47 routine patients before and after the medication.After treatment finished, every detection index was all no abnormal.During treating, no abnormal symptom and sign.
Conclusion:
One, medicine of the present invention is to the present clinical symptoms improvement of treatment of diabetes acting body aspect, and this medicine of evidence has curative effect preferably to clinical symptoms.To thirst and liking drink, fatigue and weakness, the lazy speech of breathing hard, dysphoria with feverish sensation in the chest palms and soles, the diseases such as red constipation, palpitation and insomnia, spontaneous sweating of urinating, effect is all better, and the above rate of its produce effects is respectively 81.5%, 81.2%, 69.7%, 64%, 24.8%, 44.1%, 70%.Compare with matched group, the two has notable difference (P＜0.05).
Two, medicine of the present invention is 73.86% to the total effective rate of Qi and Yin deficiency diabetes mellitus, and wherein obvious effective rate is 20.56%, effective percentage 53.3%.Relatively there were significant differences with matched group.
Three, do not find side effect in the treatment, treatment back is from detecting index, is not in the mood for, liver, renal function injury, so this medicine is safer.
The present invention has reasonable recipe, determined curative effect, the indication scope is wide, toxic and side effects is little, the advantage of no drug dependence.
The specific embodiment one: present embodiment is to be mixed by weight by following raw materials according: Radix Trichosanthis 80g～130g, Radix Ophiopogonis 50g～100g, Poria 50g～100g, Radix Astragali 50g～100g, Radix Glycyrrhizae 50g～100g, Radix Rehmanniae 50g～100g, Radix Puerariae 80g～130g, Radix Codonopsis 120g～180g, Fructus Mume 50g～100g, Fructus Schisandrae Chinensis 50g～100g.
The specific embodiment two: present embodiment is to be mixed by weight by following raw materials according: Radix Trichosanthis 129g, Radix Ophiopogonis 88g, Poria 91g, Radix Astragali 74g, Radix Glycyrrhizae 97g, Radix Rehmanniae 63g, Radix Puerariae 105g, Radix Codonopsis 142g, Fructus Mume 72g, Fructus Schisandrae Chinensis 100g.
Claims (4)
1, a kind of medicine that is used for the treatment of diabetes is characterized in that it is to be mixed by weight by following raw materials according: Radix Trichosanthis 80g～130g, Radix Ophiopogonis 50g～100g, Poria 50g～100g, Radix Astragali 50g～100g, Radix Glycyrrhizae 50g～100g, Radix Rehmanniae 50g～100g, Radix Puerariae 80g～130g, Radix Codonopsis 120g～180g, Fructus Mume 50g～100g, Fructus Schisandrae Chinensis 50g～100g.
2, a kind of medicine that is used for the treatment of diabetes according to claim 1 is characterized in that it is to be mixed by weight by following raw materials according: Radix Trichosanthis 95g～120g, Radix Ophiopogonis 65g～90g, Poria 65g～90g, Radix Astragali 65g～90g, Radix Glycyrrhizae 65g～90g, Radix Rehmanniae 65g～90g, Radix Puerariae 95g～120g, Radix Codonopsis 135g～165g, Fructus Mume 65g～90g, Fructus Schisandrae Chinensis 65g～90g.
3, a kind of medicine that is used for the treatment of diabetes according to claim 1 is characterized in that it is to be mixed by weight by following raw materials according: Radix Trichosanthis 112.5g, Radix Ophiopogonis 75g, Poria 75g, Radix Astragali 75g, Radix Glycyrrhizae 75g, Radix Rehmanniae 75g, Radix Puerariae 112.5g, Radix Codonopsis 150g, Fructus Mume 75g, Fructus Schisandrae Chinensis 75g.
4,, it is characterized in that the Radix Astragali is one or both the mixing wherein of Radix Astragali or the sweet Radix Astragali according to claim 1,2 or 3 described a kind of medicines that are used for the treatment of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101076832A CN100364592C (en) | 2003-11-11 | 2003-11-11 | Medicine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101076832A CN100364592C (en) | 2003-11-11 | 2003-11-11 | Medicine for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1615915A true CN1615915A (en) | 2005-05-18 |
| CN100364592C CN100364592C (en) | 2008-01-30 |
Family
ID=34758337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101076832A Expired - Lifetime CN100364592C (en) | 2003-11-11 | 2003-11-11 | Medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100364592C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191295A (en) * | 2013-04-18 | 2013-07-10 | 高伟 | Medicine for treating diabetes mellitus |
| CN112076151A (en) * | 2020-08-28 | 2020-12-15 | 乐泰药业有限公司 | A Chinese medicinal oral liquid for treating diabetes due to deficiency of both qi and yin, and its preparation method and quality control method |
-
2003
- 2003-11-11 CN CNB2003101076832A patent/CN100364592C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191295A (en) * | 2013-04-18 | 2013-07-10 | 高伟 | Medicine for treating diabetes mellitus |
| CN112076151A (en) * | 2020-08-28 | 2020-12-15 | 乐泰药业有限公司 | A Chinese medicinal oral liquid for treating diabetes due to deficiency of both qi and yin, and its preparation method and quality control method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100364592C (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1239187C (en) | Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method | |
| CN1119164C (en) | Medicine for treating chronic incomplete renal function and its prepn | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1341444A (en) | Health-care product with function of regulating blood sugar and its preparation method | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN101606978B (en) | Blood-sugar reducing tea and preparation method thereof | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| CN1221280C (en) | Chinese patent drug for treating heart brain blood vessel disease and its preparation method | |
| CN1615915A (en) | Medicine for treating diabetes | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1872273A (en) | Medication composition for treating cardiovascular diseases and cerebrovascular disease, and preparation method | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1264537C (en) | Capsule | |
| CN102114185B (en) | Medicament for treating insulin resistance of type 2 diabetes | |
| CN1222305C (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN1227023C (en) | Drug for treating coronary heart disease, angina and preparation method | |
| CN1650895A (en) | Method of extracting medicamout having memory strengthening function from natural plant compound preparation | |
| CN1323679C (en) | Medicine for treating enteron diseases | |
| CN1239184C (en) | Chinese medicinal composition for treating 'epigastalgia' deficiency of yin syndrom and its preparation method | |
| CN102552755A (en) | Traditional Chinese medicine composition for treating aplastic anemia | |
| CN1176687C (en) | Medicine for strengthning intelligence and delaying senility and its prepn | |
| CN108042710A (en) | A kind of Chinese medicine composition for treating deficiency of both qi and yin and retention of damp-heat in the interior type diabetes B and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LOCTITE HARBIN PHARMACEUTICAL Co.,Ltd. Assignor: Lang Weijun Contract record no.: 2011230000221 Denomination of invention: Medicine for treating diabetes Granted publication date: 20080130 License type: Exclusive License Open date: 20050518 Record date: 20110823 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20080130 |
|
| CX01 | Expiry of patent term |